These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Some considerations in the preparation of raioiodoinsulin for radioimmunoassay and receptor assay. Schneider B; Straus E; Yalow RS Diabetes; 1976 Apr; 25(4):260-7. PubMed ID: 178556 [TBL] [Abstract][Full Text] [Related]
45. Problems with the PTH assays. Cavalier E; Delanaye P; Nyssen L; Souberbielle JC Ann Endocrinol (Paris); 2015 May; 76(2):128-33. PubMed ID: 25916762 [TBL] [Abstract][Full Text] [Related]
46. Radioimmunoassay for intact and carboxyl-terminal parathyroid hormone: clinical interpretation and diagnostic significance. Hawker CD; Di Bella FP Ann Clin Lab Sci; 1980; 10(1):76-88. PubMed ID: 7362199 [TBL] [Abstract][Full Text] [Related]
47. Immunological evidences for the presence of small late carboxylterminal fragment(s) of human parathyroid hormone (PTH) in circulation in man. D'Amour P; Labelle F; Wolde-Giorghis R; Hamel L J Immunoassay; 1989; 10(2-3):191-205. PubMed ID: 2745718 [TBL] [Abstract][Full Text] [Related]
48. Biologic activities of parathyroid hormone (1-34) and parathyroid hormone-related peptide (1-34) in isolated perfused rat femur. Lopez-Hilker S; Martin KJ; Sugimoto T; Slatopolsky E J Lab Clin Med; 1992 Jun; 119(6):738-43. PubMed ID: 1317402 [TBL] [Abstract][Full Text] [Related]
49. Bioactivity of parathyroid hormone and parathyroid hormone-like peptide: agonist and antagonist activities of amino-terminal fragments as assessed by the cytochemical bioassay and in situ biochemistry. Loveridge N; Dean V; Goltzman D; Hendy GN Endocrinology; 1991 Apr; 128(4):1938-46. PubMed ID: 2004612 [TBL] [Abstract][Full Text] [Related]
50. Short-term continuous infusion of human parathyroid hormone 1-34 fragment is catabolic with decreased trabecular connectivity density accompanied by hypercalcemia in C57BL/J6 mice. Iida-Klein A; Lu SS; Kapadia R; Burkhart M; Moreno A; Dempster DW; Lindsay R J Endocrinol; 2005 Sep; 186(3):549-57. PubMed ID: 16135674 [TBL] [Abstract][Full Text] [Related]
51. [Identification and characterization of radioiodination products gonadotropin releasing hormone I]. Moctezuma O; Villanueva C; Garza-Flores J; Oliart RM; Larrea F Rev Invest Clin; 1984; 36(1):31-8. PubMed ID: 6371964 [No Abstract] [Full Text] [Related]
52. Effect of iodination on human growth hormone and prolactin: characterized by bioassay, radioimmunoassay, radioreceptor assay, and electrophoresis. Hughes JP; Tanaka T; Gout PW; Beer CT; Noble RL; Friesen HG Endocrinology; 1982 Sep; 111(3):827-32. PubMed ID: 7106054 [TBL] [Abstract][Full Text] [Related]
53. The influence of parathyroid hormone and its fragments on results from midregion and C-terminal specific radioimmunoassays. Kübler N; Krause U; Wagner PK; Beyer J; Rothmund M Exp Clin Endocrinol; 1987 Mar; 89(1):61-9. PubMed ID: 3595732 [TBL] [Abstract][Full Text] [Related]
54. Radioiodination of human growth hormone with characterization and minimization of the commonly defined "damaged products". Bartolini P; De Assis LM; Fonseca ML Clin Chim Acta; 1981 Mar; 110(2-3):177-85. PubMed ID: 7226528 [TBL] [Abstract][Full Text] [Related]
55. Characterization and purification of iodinated bovine thyrotropin by high performance liquid chromatography. Stanton PG; Hearn MT Endocrinology; 1986 Aug; 119(2):887-97. PubMed ID: 2426094 [TBL] [Abstract][Full Text] [Related]